{"nctId":"NCT01081834","briefTitle":"The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial","startDateStruct":{"date":"2010-03"},"conditions":["Diabetes Mellitus, Type 2"],"count":678,"armGroups":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin"]},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin"]},{"label":"Placebo/Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Sitagliptin"]}],"interventions":[{"name":"Canagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Sitagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients must have a diagnosis of T2DM\n* Patients in the main study must have a Hemoglobin A1c (HbA1c) between \\>=7% and \\<=10% and a fasting plasma glucose (FPG) \\<270 mg/dL (15 mmol/L)\n* Patients in the High Glycemic Cohort Substudy must have an HbA1c between \\>10% and \\<=12% and a FPG \\<=350 mg/dL (19.44 mmol/L)\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 26 (Main Study)","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.065"},{"groupId":"OG001","value":"-0.77","spread":"0.065"},{"groupId":"OG002","value":"-1.03","spread":"0.064"}]}]}]},{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-2.13","spread":"0.220"},{"groupId":"OG002","value":"-2.56","spread":"0.227"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7% at Week 26 (Main Study)","description":"The table below shows the percentage of patients with HbA1c \\<7% at Week 26. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"44.5","spread":null},{"groupId":"OG002","value":"62.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"2.448"},{"groupId":"OG001","value":"-27.2","spread":"2.412"},{"groupId":"OG002","value":"-35.0","spread":"2.391"}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)","description":"The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.19","spread":"4.204"},{"groupId":"OG001","value":"-42.9","spread":"3.763"},{"groupId":"OG002","value":"-58.8","spread":"3.741"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 26 (Main Study)","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.2"},{"groupId":"OG001","value":"-2.8","spread":"0.2"},{"groupId":"OG002","value":"-3.9","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)","description":"The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.780"},{"groupId":"OG001","value":"-3.34","spread":"0.775"},{"groupId":"OG002","value":"-5.04","spread":"0.769"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 26 (Main Study)","description":"The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"3.5"},{"groupId":"OG001","value":"2.5","spread":"3.3"},{"groupId":"OG002","value":"-2.4","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)","description":"The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"1.4"},{"groupId":"OG001","value":"11.2","spread":"1.4"},{"groupId":"OG002","value":"10.5","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7% at Week 26 (High Glycemic Substudy)","description":"The table below shows the percentage of patients with HbA1c \\<7% at Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"17.4","spread":null},{"groupId":"OG002","value":"11.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-81.7","spread":"6.459"},{"groupId":"OG002","value":"-86.3","spread":"6.553"}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)","description":"The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-118","spread":"10.179"},{"groupId":"OG002","value":"-126","spread":"9.437"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-3.0","spread":"0.6"},{"groupId":"OG002","value":"-3.8","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)","description":"The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-4.47","spread":"1.754"},{"groupId":"OG002","value":"-4.97","spread":"1.800"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)","description":"The table below shows the least-squares mean percent change in triglycerides from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.6","spread":"7.4"},{"groupId":"OG002","value":"-12.7","spread":"7.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)","description":"The table below shows the least-squares mean percent change in HDL-C from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2.4","spread":"2.9"},{"groupId":"OG002","value":"10.8","spread":"2.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":192},"commonTop":["Nasopharyngitis","Headache","Urinary tract infection","Upper respiratory tract infection","Back pain"]}}}